{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:37:22Z","timestamp":1787495842477,"version":"build-2736575974"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.radonc.2024.110373","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:02:45Z","timestamp":1718204565000},"page":"110373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much\u2026and what next?"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-712X","authenticated-orcid":false,"given":"Allen M.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110373_b0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology, and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2019.04.030","article-title":"Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy","volume":"137","author":"Wilkie","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2021.04.011","article-title":"Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer","volume":"160","author":"Van der Laan","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0020","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/ijc.33876","article-title":"Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts","volume":"150","author":"Lassen","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110373_b0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110373_b0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: a single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0040","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","article-title":"Standard of care versus reduced dose chemoradiation after induction chemotherapy in HPV-positive oropharyngeal carcinoma patients: The Quarterback Trial","volume":"95","author":"Misiukiewicz","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0060","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG 002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0065","series-title":"American Joint Committee on Cancer staging manual","year":"2017"},{"key":"10.1016\/j.radonc.2024.110373_b0070","doi-asserted-by":"crossref","unstructured":"Cramer JD, Hicks KE, Rademaker AW, et al. Validation of the eighth edition American Joint Committee on Caner staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck 2018; 40: 457-466.","DOI":"10.1002\/hed.24974"},{"key":"10.1016\/j.radonc.2024.110373_b0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PDL-1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2024.110373_b0080","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41598-020-58502-9","article-title":"Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma","volume":"10","author":"Brezar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2024.110373_b0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2012.03.033","article-title":"HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer- how valid is p16INK4A as a surrogate marker?","volume":"323","author":"Hoffman","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2024.110373_b0090","doi-asserted-by":"crossref","unstructured":"Mehanna H, Taberna M, von Buchwald C, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol 24: 239-251.","DOI":"10.1016\/S1470-2045(23)00013-X"},{"key":"10.1016\/j.radonc.2024.110373_b0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-60761-947-5_4","article-title":"In situ detection of human papillomavirus DNA after PCR-amplification","volume":"688","author":"Nuovo","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.radonc.2024.110373_b0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.humpath.2019.05.006","article-title":"In situ hybridization for high-risk HPV E6\/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer","volume":"90","author":"Randen-Brady","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.radonc.2024.110373_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2022.103555","article-title":"Smoking and other patient factors in HPV-mediated oropharynx cancer: A retrospective cohort study","volume":"43","author":"Schostag","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.radonc.2024.110373_b0110","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/lio2.695","article-title":"Quantifying smoking exposure, genomic correlates, and related risk of treatment failure in p16+ squamous cell carcinoma of the oropharynx","volume":"6","author":"Schrank","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.radonc.2024.110373_b0115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hed.25336","article-title":"Impact of American Joint Committee on Cancer eighth edition clinical stage and smoking history on oncologic outcome in human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"41","author":"Hawkins","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/lary.23570","article-title":"Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer","volume":"123","author":"Chen","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2024.110373_b0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.micinf.2017.06.001","article-title":"Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer","volume":"19","author":"Faraji","year":"2017","journal-title":"Microbes Infect"},{"key":"10.1016\/j.radonc.2024.110373_b0130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.18632\/oncotarget.27535","article-title":"The human papillomavirus confers radiosensitivity in oropharyngeal cancer cells by enhancing DNA double strand break","volume":"11","author":"Zhang","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2024.110373_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.virol.2020.05.003","article-title":"Activation of DNA damage repair factors in HPV positive oropharyngeal cancers","volume":"547","author":"Kono","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.radonc.2024.110373_b0140","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.3390\/cancers13153717","article-title":"The DNA damage response is differentially involved in HPV-positive and HPV-negative radioresistant head and neck squamous cell carcinoma","volume":"13","author":"Bamps","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2024.110373_b0145","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-11-2058","article-title":"Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival","volume":"18","author":"Gubanova","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0150","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/0008-5472.CAN-13-2479","article-title":"p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors","volume":"74","author":"Dok","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0155","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1158\/0008-5472.CAN-13-0587","article-title":"Enhanced radiation sensitivity in HPV-positive head and neck cancer","volume":"73","author":"Kimple","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0160","doi-asserted-by":"crossref","first-page":"89681","DOI":"10.18632\/oncotarget.20813","article-title":"Hypoxia-inducible factor-1\u03b1 activation in HPV-positive head and neck squamous cell carcinoma cell lines","volume":"8","author":"Knuth","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2024.110373_b0165","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2016.01.005","article-title":"Radiation-induced dedifferentiation of head and neck cancer cells into cancer stem cells depends on human papillomavirus status","volume":"94","author":"Vlashi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0170","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archoto.2009.159","article-title":"Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer","volume":"135","author":"Spanos","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.radonc.2024.110373_b0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2019.04.032","article-title":"IL-6 induced M1 type macrophage polarization increases radiosensitivity in HPV positive head and neck cancer","volume":"456","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2024.110373_b0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer","volume":"110","author":"Ward","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0185","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"13404","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2024.110373_b0190","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hed.26036","article-title":"Impact of PD-L1 expression and human papillomavirus status in anti-PD1\/PDL1 immunotherapy for head and neck squamous cell carcinoma\u2014systematic review and meta-analysis","volume":"42","author":"Patel","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0195","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2018.08.013","article-title":"Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo\/bioradiotherapy","volume":"130","author":"Ou","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0205","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2009.03.004","article-title":"Radiation response in two HPV-infected head and neck cancer cell lines in comparison to non-HPV-infected cell line and relationship to signaling through AKT","volume":"74","author":"Gupta","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0210","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/hed.25679","article-title":"The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting","volume":"41","author":"Hall","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0215","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hed.23777","article-title":"Impact of the addition of chemotherapy to radiotherapy for oropharyngeal cancer in 2003\u20132004: population-based study from the province of Ontario","volume":"37","author":"Hall","year":"2015","journal-title":"Canada Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.oraloncology.2017.01.010","article-title":"High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck","volume":"67","author":"Perez","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0225","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110373_b0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110373_b0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2017.04.015","article-title":"Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer","volume":"123","author":"Chen","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0245","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0360-3016(99)00247-3","article-title":"Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer","volume":"45","author":"Eisbruch","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2009.06.090","article-title":"Radiotherapy dose-volume effects on salivary gland function","volume":"76","author":"Deasy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0255","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2008.11.041","article-title":"Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures","volume":"75","author":"Dirix","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-4-52","article-title":"Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy","volume":"4","author":"Li","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0265","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cncr.29207","article-title":"Aspiration pneumonia after concurrent chemoradiotherapy for head-and-neck cancer","volume":"121","author":"Xu","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0270","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clon.2013.04.003","article-title":"Predictors of weight loss during conformal radiotherapy for head and neck cancers- how important are planning target volumes?","volume":"25","author":"Mallick","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0275","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semradonc.2017.08.002","article-title":"Organ-sparing in radiotherapy for head-and-neck cancer: improving quality of life","volume":"28","author":"Hawkins","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2020.04.053","article-title":"Dose-volume correlates of the prevalence of patient-reported trismus in long-term survivorship after oropharyngeal IMRT: a cross-sectional dosimetric analysis","volume":"149","author":"Kamal","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0285","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijrobp.2011.11.019","article-title":"Brachial plexus-associated neuropathy after high-dose radiation therapy for head-and-neck cancer","volume":"84","author":"Chen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0290","article-title":"Radiation-induced soft tissue injuries in patients with advanced mandibular osteoradionecrosis: a preliminary evaluation and management of various soft tissue problems around radiation-induced osteonecrosis lesions","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13014-019-1429-3","article-title":"Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer","volume":"14","author":"Hayakawa","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2011.11.026","article-title":"Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer","volume":"84","author":"Chen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0305","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamaoto.2013.4072","article-title":"Depression among long-term survivors of head and neck cancer treated by radiation therapy","volume":"139","author":"Chen","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.radonc.2024.110373_b0310","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ijrobp.2020.04.014","article-title":"Dose and volume de-escalation for human papillomavirus-positive oropharyngeal cancer is associated with favorable posttreatment functional outcomes","volume":"107","author":"Foster","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0315","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jamaoncol.2021.6416","article-title":"Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy","volume":"8","author":"Tsai","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0320","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3857\/roj.2021.00556","article-title":"Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?","volume":"39","author":"Choi","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2024.110373_b0325","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.1002\/lary.28083","article-title":"Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer","volume":"130","author":"White","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2024.110373_b0330","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2019.01.016","article-title":"Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma","volume":"134","author":"Gabani","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2012.02.009","article-title":"Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation","volume":"103","author":"O\u2019Sullivan","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0340","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hed.23209","article-title":"Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer","volume":"35","author":"Chen","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijrobp.2020.12.025","article-title":"Radiation therapy alone for human papillomavirus-related squamous cell carcinoma of the oropharynx: A single-arm, phase 2 study","volume":"110","author":"Takemoto","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0350","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hed.21688","article-title":"Transoral robotic surgery for oropharyngeal carcinoma and its implication on patient-reported quality of life and function","author":"Leonhardt","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12885-020-6607-z","article-title":"Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial","volume":"20","author":"Nichols","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0360","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211050770","article-title":"Patient selection for surgery versus radiotherapy for early stage oropharyngeal cancer","volume":"28","author":"Hilal","year":"2021","journal-title":"Cancer Control"},{"key":"10.1016\/j.radonc.2024.110373_b0365","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): Omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0370","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/cncr.29242","article-title":"The role of postoperative chemoradiation for oropharynx carcinoma: a critical appraisal of the published literature and National Comprehensive Cancer Network guidelines","volume":"121","author":"Sinha","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0375","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0380","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","article-title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","volume":"20","author":"Nichols","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0615","article-title":"Treatement deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial","volume":"8","author":"Palma","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0390","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.30954","article-title":"Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 trial","volume":"124","author":"Hegde","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0395","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijrobp.2017.10.045","article-title":"Functional outcomes after de-escalated chemoradiation therapy for human papillomavirus-positive oropharyngeal cancer: secondary analysis of a phase 2 trial","volume":"100","author":"Hegde","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0400","first-page":"1012","article-title":"Patient perspectives and treatment regret after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal cancer: findings from a phase II trial","volume":"10","author":"Shaverdian","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2024.110373_b0405","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0410","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated opharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0415","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0420","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jamaoto.2022.0159","article-title":"Association of plasma circulating tumor HPV DNA with HPV-related oropharynx cancer","volume":"148","author":"Tewari","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.radonc.2024.110373_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104373","article-title":"Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-drive treatment de-intensification","volume":"86","author":"Zeng","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2024.110373_b0430","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jnci\/djab215","article-title":"An imaging biomarker of tumor-infiltrating lymphocytes to risk stratify patients with HPV-associated oropharyngeal cancer","volume":"114","author":"Corredor","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110373_b0435","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41597-023-02611-3","article-title":"Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer","volume":"10","author":"Wang","year":"2023","journal-title":"Sci Data"},{"key":"10.1016\/j.radonc.2024.110373_b0440","first-page":"4735","article-title":"Subtypes of HPV-positive head and neck caners are assocaited with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures","volume":"22","author":"Zhang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2024.110373_b0445","doi-asserted-by":"crossref","first-page":"1007950","DOI":"10.3389\/fcimb.2022.1007950","article-title":"Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.radonc.2024.110373_b0450","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.29100","article-title":"Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status","volume":"121","author":"Huang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0455","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.oraloncology.2018.11.030","article-title":"Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status","volume":"89","author":"Meshman","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105805","article-title":"Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer","volume":"128","author":"Mattox","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0465","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-019-5536-1","article-title":"Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0470","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1186\/s12885-022-10184-4","article-title":"Association between cancer stem cell gene expression signatures and prognosis in head and neck squamous cell carcinoma","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110149","article-title":"Tumor volume and cancer stem cell expression as prognostic markers for high-dose- loco-regional failure in head and neck squamous cell carcinoma\u2014a DAHANCA 19 study","volume":"193","author":"Kristensen","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0480","first-page":"1","article-title":"Combining the radiomics signature and HPV status for the risk strateification of patients with OPC","volume":"00","author":"Wang","year":"2022","journal-title":"Oral Dis"},{"key":"10.1016\/j.radonc.2024.110373_b0485","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.3390\/cancers13225689","article-title":"Radiomics predicts for distant metastasis in locally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma","volume":"13","author":"Rich","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2024.110373_b0490","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ac39ab","article-title":"Radiomics outperforms clinical factors in characterizing human papilloma virus (HPV) for patients with oropharyngeal squamous cell carcinomas","volume":"8","author":"Bagher-Ebadian","year":"2022","journal-title":"Biomed Phys Eng Express"},{"key":"10.1016\/j.radonc.2024.110373_b0495","doi-asserted-by":"crossref","first-page":"17525","DOI":"10.1038\/s41598-020-74479-x","article-title":"Oropharyngeal squamous cell carcinoma: radiomic machine-learning classifiers from multiparametric MR images for determination of HPV infection status","volume":"10","author":"Suh","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2024.110373_b0500","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3174\/ajnr.A6695","article-title":"Pretreatment DWI with histogram analysis of the ADC in predicting the outcome of advanced oropharyngeal cancer with known human papillomavirus status treated with chemoradiation","volume":"41","author":"Ravanelli","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.radonc.2024.110373_b0505","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","article-title":"Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomarivus-related oropharyngeal carcinoma","volume":"96","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110373_b0510","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Onol"},{"key":"10.1016\/j.radonc.2024.110373_b0515","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/lary.28889","article-title":"Machine learning based radiomic HPV phenotyping of oropharyngeal SCC: a feasibility study using MRI","volume":"131","author":"Sohn","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2024.110373_b0520","doi-asserted-by":"crossref","unstructured":"Alabi RO, Almangush A, Elmusrati M, et al. An interpretable machine learning prognostic system for risk stratification in oropharyngeal cancer 2022; 168: 104896.","DOI":"10.1016\/j.ijmedinf.2022.104896"},{"key":"10.1016\/j.radonc.2024.110373_b0525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.974678","article-title":"Prediction of survival in oropharyngeal squamous cell carcinoma using machine learning algorithms: a study based on the surveillance, epidemiology, and end results database","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0530","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2022.08.033","article-title":"DeepClassPathway: Molecular pathway aware classification using explainable deep learning","volume":"176","author":"Lombardo","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110373_b0535","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/2326-6066.CIR-22-0174","article-title":"Efficacy and synergy with cisplatin of an adenovirus vectored therapeutic E12E6E7 vaccine against HPV genome-positive C3 cancers in mice","volume":"11","author":"Boilsesn","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2024.110373_b0540","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0545","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significant of p16INK4A and human papillomarivus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0550","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2011.02.010","article-title":"The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial","volume":"100","author":"Lassen","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110373_b0555","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2007.12.7597","article-title":"Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number","volume":"26","author":"Worden","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024006431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024006431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:24:37Z","timestamp":1750681477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024006431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":111,"alternative-id":["S0167814024006431"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110373","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much\u2026and what next?","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110373"}}